SINGAPORE, 7 February 2023 – VFlowTech, the Singapore-based provider of vanadium-based redox flow batteries, has raised US$10 million in a Series A funding round. Led by Japan-based venture capital (VC)...
Curzion Pharmaceuticals is a clinical-stage company, co-founded by Pappas Capital, focused on developing treatments for rare fibrotic diseases. The company's lead asset is a potent and selective LPAR1 antagonist for the treatment of diffusive systemic sclerosis.
Curzion Pharmaceuticals
San Diego, CA
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.